-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Comparing DBV Technologies (NASDAQ:DBVT) & Gene Biotherapeutics (OTCMKTS:CRXM)
Comparing DBV Technologies (NASDAQ:DBVT) & Gene Biotherapeutics (OTCMKTS:CRXM)
Gene Biotherapeutics (OTCMKTS:CRXM – Get Rating) and DBV Technologies (NASDAQ:DBVT – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.
Risk and Volatility
Gene Biotherapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Get Gene Biotherapeutics alerts:Analyst Recommendations
This is a breakdown of recent ratings for Gene Biotherapeutics and DBV Technologies, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Gene Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
DBV Technologies | 0 | 3 | 3 | 0 | 2.50 |
Valuation and Earnings
This table compares Gene Biotherapeutics and DBV Technologies' revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Gene Biotherapeutics | N/A | N/A | -$520,000.00 | N/A | N/A |
DBV Technologies | $5.71 million | 55.00 | -$97.81 million | ($0.68) | -2.46 |
Gene Biotherapeutics has higher earnings, but lower revenue than DBV Technologies.
Profitability
This table compares Gene Biotherapeutics and DBV Technologies' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Gene Biotherapeutics | N/A | N/A | N/A |
DBV Technologies | -929.78% | -57.09% | -43.02% |
Insider & Institutional Ownership
27.6% of DBV Technologies shares are owned by institutional investors. 49.8% of Gene Biotherapeutics shares are owned by insiders. Comparatively, 0.6% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Gene Biotherapeutics beats DBV Technologies on 5 of the 9 factors compared between the two stocks.
About Gene Biotherapeutics
(Get Rating)
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
About DBV Technologies
(Get Rating)
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for Gene Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gene Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Gene Biotherapeutics (OTCMKTS:CRXM – Get Rating) and DBV Technologies (NASDAQ:DBVT – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.
基因生物治療公司(OTCMKTS:CRXM-GET Rating)和DBV Technologies(納斯達克:DBVT-GET Rating)都是醫藥公司,但哪隻股票更好?我們將根據分析師的建議、估值、收益、股息、機構所有權、風險和盈利能力對這兩家公司進行比較。
Risk and Volatility
風險和波動性
Gene Biotherapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Gene BioTreateutics的貝塔係數為0.73,表明其股價的波動性比標準普爾500指數低27%。相比之下,DBV Technologies的貝塔係數為1.49,這表明其股價的波動性比標準普爾500指數高49%。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings for Gene Biotherapeutics and DBV Technologies, as provided by MarketBeat.
這是MarketBeat提供的基因生物療法和DBV技術最近的評級細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Gene Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
DBV Technologies | 0 | 3 | 3 | 0 | 2.50 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
基因生物治療學 | 0 | 0 | 0 | 0 | 不適用 |
DBV技術 | 0 | 3 | 3 | 0 | 2.50 |
Valuation and Earnings
估值和收益
This table compares Gene Biotherapeutics and DBV Technologies' revenue, earnings per share (EPS) and valuation.
該表格比較了基因生物治療公司和DBV技術公司的收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Gene Biotherapeutics | N/A | N/A | -$520,000.00 | N/A | N/A |
DBV Technologies | $5.71 million | 55.00 | -$97.81 million | ($0.68) | -2.46 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
基因生物治療學 | 不適用 | 不適用 | -$520,000.00 | 不適用 | 不適用 |
DBV技術 | 571萬美元 | 55.00 | -9,781萬元 | ($0.68) | -2.46 |
Gene Biotherapeutics has higher earnings, but lower revenue than DBV Technologies.
基因生物治療公司的收益比DBV技術公司高,但收入較低。
Profitability
盈利能力
This table compares Gene Biotherapeutics and DBV Technologies' net margins, return on equity and return on assets.
此表比較了基因生物治療公司和DBV技術公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Gene Biotherapeutics | N/A | N/A | N/A |
DBV Technologies | -929.78% | -57.09% | -43.02% |
淨利潤率 | 股本回報率 | 資產回報率 | |
基因生物治療學 | 不適用 | 不適用 | 不適用 |
DBV技術 | -929.78% | -57.09% | -43.02% |
Insider & Institutional Ownership
內部人與機構所有權
27.6% of DBV Technologies shares are owned by institutional investors. 49.8% of Gene Biotherapeutics shares are owned by insiders. Comparatively, 0.6% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
DBV Technologies 27.6%的股份由機構投資者持有。基因生物治療公司49.8%的股份由內部人士持有。相比之下,DBV Technologies 0.6%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一家公司的長期表現將好於大盤。
Summary
摘要
Gene Biotherapeutics beats DBV Technologies on 5 of the 9 factors compared between the two stocks.
基因生物治療公司在兩隻股票之間的9個因素中有5個超過了DBV Technologies。
About Gene Biotherapeutics
關於基因生物治療學
(Get Rating)
(獲取評級)
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
基因生物療法公司是一家臨牀階段生物技術公司,在美國專注於血管生成基因療法生物療法的開發和商業化,用於治療心血管疾病。該公司的主導候選產品是Generx,這是第三階段臨牀試驗中的一種血管生成基因治療候選產品,用於潛在地治療晚期冠狀動脈疾病引起的心肌缺血和頑固性心絞痛患者。它還在開發與缺血相關的心血管和腦治療適應症的Generx。基因生物治療公司與Fujifilm DiSynth生物技術公司達成協議,將生產用於第三階段臨牀評估的Generx血管生成基因治療產品。該公司前身為紅豆杉Cardium製藥集團,並於2018年1月更名為基因生物治療公司。基因生物治療公司成立於2003年,總部設在加利福尼亞州聖地亞哥。
About DBV Technologies
關於DBV技術
(Get Rating)
(獲取評級)
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBV科技公司是一家臨牀階段的生物製藥公司,致力於皮膚表面免疫治療產品的研究和開發。它的主要候選產品是Viaskin花生,這是一種免疫療法產品,已經完成了治療4至11歲兒童、青少年和成人花生過敏的第三階段臨牀試驗。這家牛奶公司還在開發Viaskin Milk,這是一種治療免疫球蛋白E(IgE)介導的牛奶蛋白過敏(CMPA)的I/II期臨牀試驗;Viaskin Egg,一種治療母雞雞蛋過敏的臨牀前階段產品;以及百日咳加強疫苗。它的其他早期研究項目包括呼吸道合胞病毒疫苗,以及克羅恩病、乳糜瀉和I型糖尿病的治療。該公司與雀巢́健康科學公司合作開發MAG1C,這是一種即用即用的特應性斑貼試驗,用於診斷嬰兒和幼兒的非免疫球蛋白E介導的CMPA。DBV技術公司成立於2002年,總部設在法國蒙圖日。
Receive News & Ratings for Gene Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gene Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《基因生物療法日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對基因生物療法和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧